These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 9010643

  • 1. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM.
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [Abstract] [Full Text] [Related]

  • 2. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
    Goa KL, Wagstaff AJ.
    Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI, Dunlay MC, Sweet CS.
    Am J Cardiol; 1995 Apr 15; 75(12):793-5. PubMed ID: 7717281
    [Abstract] [Full Text] [Related]

  • 4. Losartan: first of a new class of angiotensin antagonists for the management of hypertension.
    Carr AA, Prisant LM.
    J Clin Pharmacol; 1996 Jan 15; 36(1):3-12. PubMed ID: 8932538
    [Abstract] [Full Text] [Related]

  • 5. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM, Goldberg AI.
    Blood Press Suppl; 1996 Jan 15; 2():82-6. PubMed ID: 8913546
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL, Porter JA.
    Ann Pharmacother; 1996 Jun 15; 30(6):625-36. PubMed ID: 8792950
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of losartan.
    Goldberg A, Sweet C.
    Can J Cardiol; 1995 Aug 15; 11 Suppl F():27F-32F. PubMed ID: 7664215
    [Abstract] [Full Text] [Related]

  • 8. The future role of losartan.
    Hansson L.
    J Hum Hypertens; 1995 Nov 15; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T, Yoshinaga K.
    Blood Press Suppl; 1996 Nov 15; 2():78-81. PubMed ID: 8913545
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
    Weber MA.
    Am J Hypertens; 1992 Dec 15; 5(12 Pt 2):247S-251S. PubMed ID: 1290620
    [Abstract] [Full Text] [Related]

  • 15. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
    Byyny RL, Merrill DD, Bradstreet TE, Sweet CS.
    Cardiovasc Drugs Ther; 1996 Jul 15; 10(3):313-9. PubMed ID: 8877074
    [Abstract] [Full Text] [Related]

  • 16. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B.
    J Hum Hypertens; 1995 Nov 15; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
    Tikkanen I, Omvik P, Jensen HA.
    J Hypertens; 1995 Nov 15; 13(11):1343-51. PubMed ID: 8984133
    [Abstract] [Full Text] [Related]

  • 18. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS.
    J Hum Hypertens; 1995 Nov 15; 9(11):861-7. PubMed ID: 8583463
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
    Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY.
    Am J Hypertens; 1995 Jun 15; 8(6):578-83. PubMed ID: 7662242
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators.
    Clin Ther; 2012 Mar 15; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.